


FIBROMYALGIA SYNDROME

WHAT DO WE KNOW ABOUT CAUSES
AND TREATMENT OPTIONS?



Margueritte White M.D.

Table of Contents

1) Introduction.....	2
2) What is fibromyalgia syndrome and who is at risk?.....	3
3) Common symptoms of fibromyalgia syndrome.....	4
4) Fibromyalgia syndrome overlap with other medical disorders.....	4
5) What causes fibromyalgia syndrome?.....	6
• Abnormal pain pathways.....	6
• Autonomic nervous system dysfunction.....	7
• Chronic stress.....	7
• Oxidative stress and free radicals.....	7
• Immune system dysfunction.....	8
6) Making a diagnosis of fibromyalgia syndrome.....	8
• Criteria for diagnosis.....	8
• Other helpful diagnostic tests.....	10
7) What types of treatment are available for fibromyalgia syndrome?.....	11
Non-Pharmacological management of fibromyalgia syndrome	11
○ Education.....	11
○ Dietary changes.....	12
• Vegetarian diet.....	12
• Nutritional and vitamin supplements.....	13
○ Exercise.....	15
• Which forms of exercise are beneficial for fibromyalgia syndrome?.....	15
• Principles for prescribing and starting an exercise program.....	16
○ Acupuncture.....	17
○ Psychological therapy.....	18
• Cognitive behavioral therapy.....	18
• Cognitive hypnotherapy.....	19
• Relaxation training.....	19
• Written emotional disclosure.....	19
Pharmacological management of fibromyalgia syndrome	20
○ Analgesics.....	20
○ Antidepressants.....	21
○ Anticonvulsants.....	21
○ Sedatives.....	21
○ Pharmacologic management of POTS.....	21
General principles of therapy	22
8) Working with fibromyalgia syndrome.....	22
9) Internet online interventions for fibromyalgia syndrome.....	23
10) Glossary of terms.....	26
11) References.....	27

Introduction

Fibromyalgia syndrome (FMS) is a debilitating disorder characterized by symptoms of musculoskeletal pain, fatigue, sleep disturbance and changes in cognitive function. It is often associated with a number of other medical disorders. In the early 1970's, FMS began to emerge on the scene as a syndrome that was distinct from other rheumatologic diseases, though the World Health Organization did not recognize it as a disease until 1992. In some countries, FMS is estimated to affect about 1-2% of the general population¹⁻³ though some have suggested a prevalence as high as 5%^{4,5}. FMS has been ranked as the highest chronic illness associated with long-term disability, pain and poor self-rated health⁶. The estimated health utilization and costs for FMS have been estimated to be \$2,274 per patient per year in the U.S.⁷, 3245 euro (\$4,348 U.S.) in Spain and 4,331 euro (\$5,803 U.S.) in Germany⁸, numbers that are significantly higher when loss of work and productivity are considered.

Despite the fact that FMS is a fairly common disorder, it still remains undiagnosed in 3 of 4 people who present with symptoms. This may in part be due to the overlap that common FMS symptoms share with a number of other disorders. In addition, the criteria needed to make the diagnosis of FMS has evolved and changed over the years. To date, there is no cure for FMS and the conflicting information on effective treatments has been a source of frustration for both providers and their patients. This has led several professional organizations to develop guidelines based on evidence from well-designed studies to help clinicians and FMS patients better choose among available therapies with scientifically proven effectiveness. Towards that end, The American Pain Society⁹, the European League Against Rheumatism (EULAR)¹⁰ and the Association of Scientific Medical Societies of Germany¹¹ have put forth guidelines of available treatments for FMS based on extensive literature reviews, expert opinion and committee consensus. Both pharmacological and non-pharmacological therapies received high ratings by different organizations¹². Further, the overwhelming consensus is that no single therapeutic approach can be expected to be effective in all individuals with FMS. Therefore, a treatment plan is more likely to be successful if it is multifactorial and includes elements from different treatment modalities.

This short book is intended to give you the most updated information about what causes FMS and will review a number of effective treatment modalities along with a comprehensive list of references supporting the information presented. In addition, information about adaptations that can be made at work to decrease stress, minimize symptoms and improve productivity will be provided.

What is fibromyalgia syndrome and who is at risk?

FMS is a chronic disorder characterized by widespread muscle pain, joint stiffness, fatigue and sleep disturbance.

- FMS occurs in almost all ethnic groups and is not limited to industrialized countries, with the exception of China where epidemiologic studies have revealed a very low prevalence¹³. It is not known why the prevalence of FMS in China is so low, but it is thought that this may be due to differences in environmental exposure, genetics or a combination of both.
- Though FMS affects all age groups, the incidence increases with age and it is more common in individuals over 50 years old¹⁴.
- Women are diagnosed with FMS far more often than men, except during childhood where girls and boys are equally affected. Fortunately, children are more than likely to outgrow their symptoms. Even though one study reported that the majority of the participants with FMS who were interviewed could not identify a specific factor that precipitated the onset of symptoms¹⁵, certain physical and psychological factors or stressors may trigger symptoms or increase one's susceptibility.
- For instance, psychiatric problems such as anxiety, somatization (experiencing physical symptoms for which no organic cause can be found), panic disorder, posttraumatic stress are more common among individuals with FMS compared to those with other rheumatic diseases¹⁶ and depression has been shown to worsen symptoms¹⁷⁻²⁰.
- Infections have also been linked to triggering FMS. In particular viruses such as Coxsackie²¹ Parvovirus²² or bacteria such as Borrelia²³ may be involved.
- Vaccinations have also been considered as possible triggers²⁴, though more recently the evidence supporting this has been questioned²⁵.
- Physical trauma²⁶, emotional distress, chronic stress²⁷ and exposure to certain environmental chemicals²⁸ may also trigger FMS symptoms.

In addition to environmental factors, studies of families have pointed to a role for genetics. For instance, the incidence of FMS is greater in first-degree relatives of those diagnosed with the disorder²⁹⁻³⁰. First degree relatives are not only 8 times more likely to develop FMS compared with the general population, but they also can suffer from greater tenderness even in the absence of pain and are much more likely to have other pain syndromes such as headaches and irritable bowel syndrome.

Did you know?



Despite the fact that FMS is a fairly common disorder, it still remains undiagnosed in 3 of 4 people who present with symptoms.



Common symptoms of fibromyalgia syndrome (FMS)

FMS is a disorder that has widespread effects throughout the body. Almost everyone with a diagnosis of FMS has complaints of **pain, chronic fatigue** and **sleep disturbance**. Painful morning stiffness that can last up to several hours during the day is a common feature. The pain is not confined to the musculoskeletal system however, since tension and migraine headaches, jaw and facial tenderness are not uncommon complaints. Individuals often complain of **sleeping poorly** and waking up “unrefreshed” in the morning. Yet, despite feeling sleep-deprived, people often have difficulty taking a nap during the day. **Gastrointestinal complaints** can range from abdominal pain, bloating and constipation to nausea and diarrhea. Bladder problems such as increased urinary frequency and urgency are also found.

Some people will experience parasthesias such as numbness or tingling in the face, arms, hands or feet. There may also be a feeling of swelling in the hands and feet, though no swelling is apparent on examination. There may be increased **sensitivity to odors, noises, bright light** and **cold**. There can be reduced tolerance for exercise that is sometimes accompanied by heart palpitations and dizziness and increased muscle pain after exercising is often reported. In addition to these physical symptoms, individuals with FMS often complain of “**brain fog**” or problems with memory, concentration and difficulties performing simple mental tasks. **Depression** and **anxiety** are also very common.

FMS symptoms overlap with other medical disorders

Because the symptoms of FMS overlap with a number of other disorders, it’s important to investigate if other medical conditions are present before arriving at a definitive diagnosis (Table 1). In many cases, the history and physical examination combined with carefully chosen laboratory studies can help the clinician distinguish among the various contenders. For example, rheumatoid arthritis and other inflammatory rheumatic diseases may present with widespread musculoskeletal pain and morning stiffness similar to FMS, but can often be distinguished by the presence of joint inflammation, swelling and deformity or the presence of rashes that are not seen in FMS.

Laboratory studies and x-rays are also useful in helping to nail the diagnosis. Individuals with hypothyroidism can be chronically fatigued with poor quality sleep and generalized muscular pain. Here, obtaining thyroid function studies will help differentiate the disorders. Adrenal insufficiency can lead to chronic fatigue. Here again, laboratory studies are useful in helping to sort things out. Certain psychiatric disorders such as post-traumatic stress disorder (PTSD), anxiety and depression may also underlie a number of the symptoms seen in FMS and in some cases, treating the mental health disorder can alleviate the symptoms altogether³¹. In older individuals, diffuse muscular pain can also be a presenting complaint of multiple myeloma, a relatively rare cancer of the blood. A careful family and/or personal history of cancer can be helpful.

In summary, it is important for both patients and their providers to be aware of the overlap in symptoms between FMS and a number of other physical and mental disorders, so that the correct diagnosis can be made and the appropriate treatment instituted.

Table 1: Differential diagnoses of fibromyalgia and corresponding diagnostic testing options.

Differential diagnosis	Differential diagnosis
Adrenal dysfunction	Morning serum cortisol, urinary catecholamine metabolites
Anemia	CBC with differential, RBC indices (MCV, MCH, MCHC)
Bone marrow disease	WBC differential, ESR, CRP, CMP
Chronic fatigue syndrome	Clinical history
Functional disorders (e.g., intestinal dysbiosis, subtle endocrine imbalances, postviral immune suppression)	Standard laboratory testing yields unclear results
Hypothyroidism	Thyroid function tests (T3, T4, TSH)
Lyme disease	Lyme titer, CMP
Psychiatric conditions (e.g., anxiety, depression, PTSD)	Refer to DSM-IV
Multiple sclerosis	MRI scan, lumbar puncture, evoked potential testing Muscular tender points on physical examination
Phenomenological Referred Myofascial Pain Rheumatoid autoimmune disorders (e.g., rheumatoid arthritis, ankylosing spondylitis, scleroderma)	Rheumatic profile (rheumatoid factor, ESR/CRP), ANA
Sleep disorders	EEG sleep studies
Spinal facet pain or sacroiliac joint pain	Radiologic studies (MRI scan, CT scan), bone scans (minimal diagnostic assistance)
Spinal disc herniation	MRI scan
Systemic inflammation or infection	WBC differential, ESR, CRP, CMP
Vitamin and/or mineral deficiency	B vitamins, magnesium, malic acid, complete nutrition assessment

ANA, antinuclear antibody; CBC, complete blood count; CMP, complete metabolic profile; CRP, C-reactive protein; CT, computerised tomography; DSMIV, diagnostic and statistical manual of mental disorders; EEG, electroencephalogram; ESR, erythrocyte sedimentation rate; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; MCV, mean corpuscular volume; MRI, magnetic resonance imaging; PTSD, posttraumatic stress disorder; RBC, red blood cell; T3, triiodothyronine; T4, thyroxine; TSH, thyroid stimulating hormone; WBC, white blood cell.

When considering the different diagnoses in someone presenting with symptoms consistent with FMS, it is not always the case that it will be an either/or situation. Several of the very same disorders previously discussed have been shown to co-exist with FMS (Table 2). Rheumatic conditions, chronic fatigue syndrome, irritable bowel syndrome, headache and psychiatric conditions such as anxiety and depression are anywhere from two to seven times more likely to be present in individuals with a diagnosis of FMS¹.

Table 2: Conditions often associated with fibromyalgia.

Musculoskeletal	Genitourinary	Gastrointestinal	Miscellaneous
Nondermatomal paresthesia	Dysmenorrhea	Irritable bowel syndrome	Tension/migraine headaches
Temporomandibular joint syndrome	Interstitial cystitis	Esophageal dysmotility	Cognitive dysfunction
Hypermobility syndrome	Vulvodynia		Anxiety disorders
Rheumatoid Arthritis	Female urethral syndrome		Hyperventilation
Systemic lupus erythematosus	Vulvar vestibulitis		Allergy
Sjögren syndrome	Premenstrual syndrome		Vestibular disorders
Osteoarthritis			Ocular disorders
Chronic fatigue syndrome			Reynaud phenomenon
Carpal tunnel syndrome			Lyme disease
Myofascial pain syndrome			Mitral valve prolapse

What causes FMS?




Abnormal pain pathway

Pain is one of the central features of FMS. The association between FMS and other painful conditions such as irritable bowel syndrome, tension-type headaches, migraines, temporomandibular disorder, chronic pelvic pain, interstitial cystitis, painful bladder syndrome and chronic prostatitis³² has led researchers to investigate whether abnormalities in the pain processing pathways may be contributing factors. Over the years, research has indeed uncovered certain alterations in the way pain signals are transmitted and perceived by individuals with FMS. Under normal circumstances, the perception of pain involves two main groups of neural pathways called "ascending and descending pathways" (Figure 1). Peripheral nerves, those outside of the spinal cord, transmit signals to the spinal cord that are in turn sent through the ascending pathway to the brain for processing.

The descending pain pathways can modulate the intensity with which the brain perceives those signals. In FMS, the two main pathways function abnormally in such a way that the pain signal coming in from the periphery is amplified, something that has been termed "central amplification". Individuals with FMS perceive pain at a lower threshold than healthy controls³³. They also have an increased response to painful stimuli, something called "hyperalgesia" and a heightened sensitivity to stimuli that are not normally painful, termed "allodynia". There can also be increased sensitivity to pressure, heat, cold, even auditory and electrical stimuli^{33,34}. Imaging studies have supported these observations by showing that the pain processing brain centers in people with FMS are more active when they are presented with the same stimulus as a healthy control³⁵.

What exactly is underlying these changes? Normally, our perception of pain is a result of a balance between painful signals travelling up the spinal cord to our brain and a sort of dampening or inhibitory pathway that modulates its impact. In FMS, there appears to be both increased excitability of central nerve cells and a decrease in inhibitory mechanisms. Higher levels of substances called neurotransmitters that work to increase the effect of sensory input have been found in the cerebral spinal fluid and brains of individuals with FMS compared to healthy controls. Conversely, levels of neurotransmitters that process signals in the inhibitory descending pathway, such as norepinephrine and serotonin, are lower in the cerebral spinal fluid of those with FMS (Figure 1)^{32,36,37}. Since many of these neurotransmitters have an effect on mood, energy and sleep, these imbalances may also explain fatigue, mood disorders and sleep problems that are often seen with FMS.

Figure 1- Neural pathways and neurotransmitters that influence pain sensitivity



In addition to the interactions between the central and peripheral nervous systems, enhanced pain perception may chronically activate the sympathetic nervous system, the part of our nervous system particularly involved in stress. This chronic activation of the sympathetic nervous system can lead to muscle contractions that may contribute to fatigue. In addition, when muscles do not receive enough oxygen, glial cells, those cells that surround and protect nerve cells in the brain, release inflammatory chemicals that probably contribute to the symptoms of fibromyalgia in unknown ways.

Autonomic nervous system dysfunction

A number of FMS symptoms appear to be due abnormal regulation of the autonomic nervous system (ANS)³⁸, the part of our nervous system that regulates heart rate, blood pressure, breathing and bowel function. This may explain the increase in heart rate that can sometimes occur when someone with FMS goes from a sitting to a standing position. The heart rate can increase rapidly more than 30 beats per minute, even though the blood pressure stays normal or may even be slightly elevated. This phenomenon is called postural orthostatic tachycardia syndrome (POTS) and can often lead to dizziness and palpitations. POTS may also contribute to exercise intolerance, headache, sleep abnormalities and cognitive difficulties. Many people can develop symptoms while standing, eating, showering or performing light exercise. In some individuals, the symptoms can be very debilitating. Fortunately, most people can expect improvement in their symptoms with the treatment options that are available (see pharmacological management of POTS).

Chronic stress

The biochemical consequences of stress may also be important in the development of FMS symptoms and dysregulation of the hypothalamic-pituitary axis (HPA) is the central player in this scenario. Normally, during times of stress, cortisol levels increase. Different studies have shown that higher levels of cortisol are found in people with FMS, especially in the evening, and that these may be associated with disrupted sleep patterns³⁹⁻⁴¹. Low levels of growth hormone may also contribute to sleep disruption in FMS. Growth hormone tends to be secreted during stage 4 of sleep or deep sleep⁴², and this is the stage of sleep that is most disturbed in people with FMS. This stress response may have even broader implications. For instance, studies that have examined skin biopsies from tender points in individuals with FMS have found changes consistent with the effects of chronic stress, namely evidence of demyelinated nerve cells and inflammation of peripheral nerve fibers⁴³.

Oxidative stress and free radicals

Oxidative stress and abnormal regulation of our immune system are also thought to contribute to FMS. Some studies have suggested that individuals suffering from FMS have a high level of oxidative stress and free radicals in their bodies^{44,45} that may be contributing to musculoskeletal symptoms. These free radicals accumulate in little organelles in our cells called mitochondria that produce 90% of our energy. Mitochondria depend on a number of important compounds like coenzyme Q, niacin and magnesium to name a few, in order to neutralize these free radicals that can cause damage to many important structures within the cell. The observation that some individuals with FMS have low levels of some antioxidant nutrients like magnesium⁴⁶ and selenium^{47,48} implies that oxidative stress may be contributing to the disease process.

Immune system dysfunction

Some studies have suggested that certain cytokines may be deregulated in FMS⁴⁹. Cytokines are protein molecules that modulate our immune system and are known to play a role in a number of symptoms such as fatigue, fever, sleep, pain, stress and aching.

All of these observations provide different windows through which we are beginning to understand what may be behind some of the most troubling FMS symptoms. But the story is likely to be more complicated because genetic and environmental factors also determine to a large degree how processes like central amplification actually function in individuals⁵⁰. Many of the genes that have been investigated such as the serotonin transporter gene^{51,52}, dopamine D4 receptor gene⁵³ and the catechol-O-methyltransferase^{54,55} are all associated with neurotransmitters that, as already mentioned, are the key players in our pain processing pathways.

In summary, our understanding of what factors may underlie FMS has improved considerably over the years. Abnormalities in pain processing pathways, oxidative stress and our immune system may all be playing a role, albeit against a background of environmental and genetic influences.


Making a diagnosis of fibromyalgia syndrome

Criteria for diagnosis

Because FMS often presents as a constellation of symptoms, it has been challenging to come up with specific diagnostic criteria. In many cases, it was a diagnosis of exclusion after other conditions were ruled out. Therefore, in 1990, the American College of Rheumatology (ACR) established the following guidelines for establishing a diagnosis of FMS:

- 1) musculoskeletal pain that has been present for at least 3 months and is located in all four body regions (divided horizontally at the waistline and vertically at the midline) and in the axial skeleton.
- 2) pain elicited on palpation in 11 out of 18 tender points designated by the ACR (Figure 2).

Figure 2- Fibromyalgia tender points.



Some criticized this scheme as being too restrictive because it focused primarily on pain while ignoring other important symptoms. Further, an estimated 80% of people with fibromyalgia actually had fewer tender points than required by this criteria⁵⁶. As a result, in 2010, the ACR put forth a new set of criteria that included symptoms of sleep disturbance, fatigue and cognitive problems (Table 3). In place of the tender point count, patients now described 19 body regions in which pain had been experienced during the past week. Each area was given one point for a total of 19 points. The final number was referred to as the Widespread Pain Index (WPI).

The second part of the evaluation was the symptom severity score (SS). Here individuals ranked symptoms on a scale of 1-3: for example, fatigue, waking unrefreshed, memory or cognitive loss, headache, weakness, bowel problems, nausea, dizziness etc. A diagnosis of FMS was made if the following conditions were met: *a WPI of at least 7 and SS scale score of at least 5 OR WPI of 3-6 and an SS scale score of at least 9.*

Table 3 - New American College of Rheumatology (ACR) diagnostic criteria for symptom severity (SS)

Fatigue	Waking unrefreshed	Cognitive symptoms
0= No problem	0= No problem	0= No problem
1= Slight or mild problems; generally mild or intermittent	1= Slight or mild problems; generally mild or intermittent	1= Slight or mild problems; generally mild or intermittent
2= Moderate; considerable problems;often present and/or at a moderate level	2= Moderate; considerable problems;often present and/or at a moderate level	2= Moderate; considerable problems;often present and/or at a moderate level
3= Severe: pervasive, continuous; life disturbing problems	3= Severe: pervasive, continuous; life disturbing problems	3= Severe: pervasive, continuous; life disturbing problems

In 2011, a further modification of these criteria was proposed 30 (Tables 4-5). The criteria became completely patient driven and no longer required a physician to assess the extent of the symptoms, which had been a previous component of the SS scale. Three more questions were added about abdominal pain, depression and headaches. In addition, a new FMS symptom scale was developed that added the WPI and SS scores together for a total score of 31. An FS score of 13 or higher was found to be the best predictor of FMS. Since these new criteria were primarily developed for the purpose of improving research tools for epidemiologic studies, they have not been widely adopted. In the end, the most widely used criteria for the diagnosis of FMS is that provided by the WPI and SS scales.

Table 4 - Key features of the ACR 1990 classification criteria for fibromyalgia

<i>Widespread pain</i>	<i>Tender points</i>
Pain in the left/right side of the body, pain above/below the waist. In addition, axial skeleton pain (cervical spine or anterior chest or thoracic spine or low back) must be present.	Pain, on digital palpation (4kg/cm ² applied over 4 seconds), must be present in at least 11 of the following 18 specified tender-point bilateral sites: occiput, low cervical, trapezius, supraspinatus, second rib, lateral epicondyle, gluteal, greater trochanter, and knee.

Table 5

ACR 2010 and modified classification criteria for fibromyalgia
<p>Widespread pain index (WPI)</p> <p>Note the number of areas in which the patient has had pain over the past week (0-19 points). The following are the areas to be considered: shoulder girdle, hip (buttock,trochanter), jaw, upper back, lower back, upper arm, upper leg, chest, neck, abdomen, lower arm, and lower leg (all these areas should be considered bilaterally).</p>
<p>SS scale score</p> <p>Fatigue, waking unrefreshed, cognitive symptoms (e.g., working memory capacity, recognition memory, verbal knowledge, anxiety, and depression). For each of these 3 symptoms, indicate the level of severity over the past week using the following scale:</p> <ul style="list-style-type: none"> • 0= no problem • 1= slight or mild problems, generally mild or intermittent • 2= moderate; considerable problems, often present and/or at a moderate level • 3= severe; pervasive, continuous, life-disturbing problems <p>Considering somatic symptoms in general, indicate whether the patient has the following:</p> <ul style="list-style-type: none"> • 0= no symptoms • 1= few symptoms • 2= a moderate number of symptoms • 3= a great deal of symptoms <p>Final score between 0 and 12</p>
<p>Criteria</p> <p>A patient satisfies diagnostic criteria for fibromyalgia if the following 3 conditions are met:</p> <ol style="list-style-type: none"> i WPI \geq 7/19 and SS scale score \geq 5 OR WPI 3-6 and SS scale score \geq 9 ii symptoms have been present at a similar level for at least 3months iii the patient does not have a disorder that would otherwise explain the pain

Other helpful diagnostic tests

Once the diagnosis of FMS is made, other diagnostic tests may be useful in further investigating certain specific symptoms. For instance, complaints of dizziness and heart palpitations, especially when going from sitting or lying down to a standing position, can be evaluated with a tilt table test⁵⁷ or standing test³⁸. If a sustained increase in heart rate of at least 30 beats per minute is seen, this suggests a diagnosis of POTS.


Further, for individuals with cognitive dysfunction, the standard tests used to evaluate memory such as the Wechsler Memory Scale may not be sensitive enough to detect cognitive deficits in someone with FMS. In fact, individuals with FMS usually perform well on many of these standard tests. As it turns out, this is because distractions play a large role in the memory problems associated with FMS and so, when faced with a test that is administered under distraction-free conditions, FMS individuals will often perform well. To test the importance of distractions, researchers tested 35 patients with FMS and 35 patients with complaints of memory loss for other reasons as a control group⁵⁸. When there were no distractions during the test, only 31.4% of FMS patients had difficulty with at least one of the tasks. When a source of distraction was added, that number rose to 85.7%. The test that picked up this discrepancy was the Auditory Consonant Trigram (ACT). Another test named the Stroop Test was used to reveal difficulties with reading words and naming colors that were unique to FMS patients compared to other patients with memory loss⁵⁹. These two tests represent recent diagnostic tools that can better identify and evaluate cognitive deficits in people with FMS that previously went undetected.

What types of treatment are available for FMS?

The main goals of FMS treatment should be to relieve pain, improve sleep disturbances and physical function as well as identify and treat any co-existing disorders. In order to be maximally effective and beneficial, all approaches to management need to be multifaceted and geared to each individual's physical, emotional and social circumstances. What follows is a wide range of treatment components that have been shown to be effective in managing FMS, several of which have been recommended to varying degrees in guidelines put forth by professional organisations such as the American Pain Society, the European League Against Rheumatism and the Association of Scientific Medical Societies of Germany.

Non-Pharmacological Management of FMS

o Education



It's important to seek out educational programs that offer a wide range of information about topics such as FMS symptoms, the course of the illness, associated disorders, potential causes, psychosocial factors that influence pain, the various pharmacologic and non-pharmacologic treatment options, along with self-management instructions. For instance, if you have symptoms of POTS, you can learn about the importance of avoiding aggravating factors such as extreme heat or dehydration, stopping or changing medications that could be contributing to the symptoms such as diuretics and vasodilators, and you can be encouraged to wear elastic support hose and engage in an exercise program that is properly supervised and gradual³⁸.

Learning about self-management strategies is an important part of any educational program. One example of a self-management strategy might centre on the area of sleep. Certain behavioural changes can be recommended that will optimize conditions for more restful sleep. For instance, you can plan on going to bed at a regular time and always sleep in your bed (avoiding using a chair for example); you can take a warm bath before going to bed, keep the room dark and private and try to maintain the room temperature constant. This is obviously just one small example of the wide range of self-management tools that can be shared

Educational programs are most effective when they are combined with other interventions. It's been shown, for example, that education in self-management leads to a better response to group exercise such as walking, strength training and stretching activities⁶⁰. In addition, those who participate in clinical education in addition to their usual care have reported improvement in physical functioning, fatigue, stiffness, anxiety and depression. Another important facet of education is open and direct communication between you and your providers. Your expectations need to be clearly identified, so that realistic goals can be set and the response to therapy properly assessed. Openly discussing the possibility that complete pain relief may not always be achieved opens the door for considering a variety of useful strategies that can improve your quality of life and sense of emotional and physical well-being.

For instance, one study found that women who began to see pain as a warning signal that there was too much stress in their lives, found that they were better able to change goals and daily obligations in order to maintain their improved status⁶¹. In addition, acceptance-based approaches for pain management can be successfully used with other intervention strategies. Studies have shown that greater acceptance of chronic pain is associated with improved emotional, physical and social functioning⁶². This approach involves admitting that a cure for the pain may not occur, shifting your focus away from pain to non-pain aspects of your life and rejecting the idea that pain is a personal weakness. FMS education should therefore be an integral part of any treatment plan and has been shown to have a positive effect on symptoms and overall sense of well-being.

o Dietary changes



Many people diagnosed with FMS consider making changes in their diet and adding nutritional supplements to help manage their symptoms. In a recent survey of one hundred and one women with FMS, 30% had changed their dietary habits and most of them used nutritional supplements with the most common being magnesium⁶³. An immediate benefit of changing your diet is weight loss. Being overweight can worsen FMS symptoms and obese individuals with FMS (body mass index or BMI>30) have been shown to have a higher pain sensitivity and decreased quality of life⁶⁴.

But the effects of dietary changes may have even broader implications. Because chronic inflammation and oxidative stress may be important contributors to the development of FMS, diets rich in antioxidants may provide a number of benefits. Individuals eating vegan diets based on uncooked living food have reported improvement in joint stiffness and pain and also showed higher levels of beta- and alpha-carotenes, lycopene and lutein, vitamin C and E in their serum compared to those eating a regular diet⁶⁵.

Vegetarian diet

Studies have also shown that this kind of dietary intervention is beneficial in FMS. For instance, eating a raw, pure vegetarian diet consisting of fruits, salads, carrot juice, tubers, grain products, seeds and dehydrated barley grass juice for seven months led to significant improvements in almost all symptoms except body pain⁶⁶. Another study however, found that when compared to antidepressant medication, a six-week intervention of a vegetarian diet did not improve fatigue, insomnia or sleep⁶⁷. These latter results may suggest that a six-week dietary intervention may not be long enough to see noticeable differences in symptoms.

Avoiding certain substances may also be of benefit. Monosodium glutamate (MSG) and aspartame are thought to potentially act as excitatory neurotransmitters that may be toxic to nerve cells when used in excess. While MSG is usually associated with Chinese restaurant food, it can also be found in many common food products such as canned soup, beef and chicken stock, frozen dinners, fast foods and instant meals such as seasoned mixtures of instant noodles. In a small study of just four patients with FMS, eliminating these products from their diet led to a complete resolution of symptoms within months⁶⁸. More studies are obviously needed with larger groups of individuals to confirm these results.

Nutritional and vitamin supplements



What about the impact of certain nutritional deficiencies? Vitamin D levels have been reported to be lower in individuals with FMS⁶⁹. However, whether low vitamin D levels are directly linked to musculoskeletal pain is unknown⁷⁰ and more studies are needed to determine how vitamin D deficiency may be impacting FMS symptoms. Some,^{48,71} but not all studies^{47,72} have shown decreased levels of trace elements like magnesium, zinc and selenium in individuals with FMS.

What about the impact of certain nutritional deficiencies? Vitamin D levels have been reported to be lower in individuals with FMS⁶⁹. However, whether low vitamin D levels are directly linked to musculoskeletal pain is unknown⁷⁰ and more studies are needed to determine how vitamin D deficiency may be impacting FMS symptoms. Some,^{48,71} but not all studies^{47,72} have shown decreased levels of trace elements like magnesium, zinc and selenium in individuals with FMS. These elements are very important in maintaining the oxidant/antioxidant balance in the body and taking vitamin C, E and magnesium supplementation may be of possible benefit⁷³. Lower levels of melatonin have been found in individuals with FMS and melatonin replacement has been reported to reduce complaints. Since melatonin has a good safety profile, the authors of this study recommended using it as a treatment that may help with sleep disturbances, especially when a deficiency is found⁷⁴. Though the number of reliable studies is limited, there is evidence that nutritional supplements may be beneficial in improving FMS symptoms. Further, they have been generally found to be safe with mild side effects.

5-HTP or 5-hydroxytryptophan is a chemical that the body makes from an essential amino acid called tryptophan. Once tryptophan is converted to 5-HT, it is changed to serotonin, a neurotransmitter that enhances communication between brain cells. While tryptophan is found in the foods we eat, it is difficult to increase 5-HT levels by diet alone, which is why a supplement, made from the seeds of an African plant called *Griffonia simplicifolia* has been made available. 5-HT is often used to treat depression and has also been investigated to a limited extent in FMS. Two studies and one review have suggested the 5-HT improves a number of FMS symptoms when given alone or in combination with certain antidepressants⁷⁵⁻⁷⁷. In one double-blind study of 50 people with FMS, taking 300 mg per day of 5-HT for 30 days led to decreased pain and tender points along with improved sleep, morning stiffness, anxiety and fatigue when compared to those individuals who were taking placebo⁷⁸. Side effects associated with 5-HT are mild, short term and usually are limited to digestive problems and possible allergic reactions.

Chlorella pyreïnoidosa is a single-cell green algae that grows in fresh water. It has the highest concentration of chlorophyll of any known plant and is also rich in protein, vitamins, minerals and other essential nutrients. As a dietary supplement, it has been linked to anti-cancer activity, promotion of growth and healing, and stimulation of the immune system. In a small but well-designed double-blind trial, 37 participants with FMS were randomised to receive 10 gram chlorella tablets and a 100 ml extract or placebo plus extract, daily for three months⁷⁹. More participants taking chlorella versus placebo reported a decrease in pain associated with tender points and improved functionality. In addition, for some subjects, deep sleep and anxiety also improved. Chlorella also appears to be safe with no toxic effects reported in animals or humans. Mild gastrointestinal symptoms such as loose bowels, cramping or nausea have been reported with preparations that include broken cell walls.

Acetyl-L-carnitine (ALCAR or LAC) is a nutritional supplement that is synthesized in order to help the body make more of a chemical called L-carnitine. Carnitine plays an important role in energy production within cells and LAC has been used to help manage a wide range of conditions such as depression, memory loss and stroke. It also acts as an antioxidant and may provide potential benefits for the central nervous system and heart. The main dietary source of carnitine is from red meat, especially mutton. Symptoms of carnitine deficiency include weakness, fatigue and exercise intolerance. While these are also common symptoms among people with FMS, it is not known whether carnitine deficiency is actually a feature of FMS. Still, in a double-blind trial, 102 patients with FMS were randomised to receive 1500 mg daily of LAC for eight weeks or placebo (following a two week protocol of oral and intramuscular LAC or placebo). Both groups reported an improvement in symptoms. However, those receiving LAC found that the decrease in tender points, depression and pain persisted for a longer period of time⁸⁰. LAC was well tolerated in this study. In general, side effects are mild and include nausea, vomiting, abdominal cramps and headache.

Super Malic is a nutritional supplement that is a combination of magnesium, an essential mineral, and malic acid, a substance that is made by the body and also found in apples and other fruits. Evidence that Super Malic alleviates FMS symptoms is limited. One small study reported beneficial effects of Super Malic in relieving muscle pain. This trial was carried out in two phases. Twenty-four patients with FMS were randomised to receive 200 mg of malic acid and 50 mg of magnesium or a placebo⁸¹. The first phase of the study lasted four weeks and was carried out in a blinded fashion so that the participants did not know whether they were taking placebo or Super Malic. At the end of this phase, there were no significant improvements in either group. In the second phase of the study, participants knew what they were taking and were allowed to increase the dose as needed. After six months, the group taking Super Malic reported significant improvement in the severity of pain and tenderness. Only mild gastrointestinal side effects were reported.

SAMe or S-adenosylmethionine is derived from an amino acid called methionine and adenosine triphosphate (ATP) and is commonly used to treat depression and osteoarthritis. Though the body makes all of the SAMe that it requires, deficiencies in methionine, B-12 and folate may decrease SAMe levels. Three out of four double-blind trials found SAMe to be helpful in improving symptoms of FMS. In most of the trials, the supplement was given intravenously or by muscle injection, sometimes in combination with pills⁸²⁻⁸⁵. In one trial, 44 people with FMS took 800 mg tablets of SAMe or placebo for six weeks⁸⁴. Those taking SAMe reported improvements in disease activity, mood, pain at rest and morning stiffness. SAMe appears to be quite safe as determined in human and animal studies with the most common side effect being stomach or digestive distress.

Collagen, **ascorbigen** and **co-enzyme Q10** with **Ginkgo biloba** have also been shown to be beneficial in reducing symptoms such as pain and improving quality of life^{80,84,86-89}. In a very small randomised study, those who used topical capsaicin (found in cayenne peppers) in addition to their regular medical treatment reported significant improvements in pain compared to those taking a placebo⁹⁰. And though two thirds of participants who took **D-ribose** daily for three to four weeks reported significant improvement in FMS symptoms⁹¹, this study was not randomised and no placebo was used.

In summary, the evidence to date suggests that adopting a vegetarian diet, losing weight, and using nutritional supplements may improve symptoms of FMS. While some deficiencies in trace minerals such as magnesium, selenium, zinc and lower levels of vitamin D and melatonin have been reported in individuals with FMS, it is unclear how much these contribute to the disorder. Lastly, it is important to work together with your healthcare provider before using nutritional supplements and you should both carefully review the evidence regarding the potential benefits, risks and importantly, possibility of dangerous interactions with other medications that you may be taking.

o Exercise

Which forms of exercise are beneficial for fibromyalgia syndrome?



Aerobic exercise and strength training have been most consistently linked to improvements in FMS symptoms. In 2010, a review of 28 randomised controlled trials found that exercise, practiced two to three times per week for at least four to six weeks reduced pain, fatigue, depressed mood and improved quality of life, though there did not appear to be a significant effect on sleep disturbances⁹². The exercise level needed to be at least of moderate intensity and consistently maintained in order for the positive effects on pain to persist. It is not necessary to stick to only one form of exercise, as a combination of aerobic exercise, strengthening and flexibility has also been shown to improve physical and mental health⁹³. The exercise program must be tailored to your baseline level of fitness and must take into account the severity of your symptoms, so that you will not be discouraged or harmed. Group exercise may be better than home-based programs because of the increased supervision that is often available. If you have a good baseline physical level of functioning, you may be able to participate in group exercise programs offered to healthy individuals. If your functional level is more limited, however, you should start very gradually with walking, stretching and other low effort activity.

There are types of mind body exercise that have also been found to be beneficial in reducing FMS symptoms. **Tai Chi**, for one, is a form of ancient Chinese martial arts that combines slow, graceful, purposeful movements with controlled breathing and relaxation. It works by redistributing the body's vital energy termed "qi". Individuals with FMS who participated in twice weekly 90 minute sessions for 12 weeks that was based on an eight-form Yang style program⁹⁴ had significant improvements in pain, sleep, functional mobility and balance compared to those who were enrolled in an educational program alone⁹⁵. The improvement in functional mobility also suggests that Tai Chi may be helpful in decreasing falls and improving performance of daily tasks⁹⁶.

A particular form of **Qigong**, Chaoyi Fanhuan Qigong⁹⁷ has also been associated with improved pain, sleep, physical and mental function in individuals with fibromyalgia⁹⁸. In this randomised trial, participants practiced at home for 45-60 minutes for eight weeks. The important observation here was that the benefits extended even beyond the end of the program.

Water exercises and **balneotherapy** – spa bathing - also have a place in FMS therapy. There is no clear consensus that water exercises are more beneficial than land exercises, though many of the studies have not provided sufficient information about the details of the water therapy to really compare the outcomes⁹⁹. In balneotherapy, natural mineral and thermal waters or mud application is often used. Four randomised trials have concluded that there is a benefit to balneotherapy¹⁰⁰.

It's not clear exactly how this therapy relieves chronic pain, but hot stimuli is known to increase the pain threshold in nerve endings. The pain relief may therefore be due to the effects of the water temperature combined with the hydrostatic pressure on the skin. Spa therapy also leads to the release of beneficial hormones such as adrenocorticotrophic hormone (ACTH), prolactin and growth hormone (GH). Since FMS seems to involve dysregulation of the hypothalamic-pituitary-adrenal axis (HPA) that oversees the production many of these hormones, it may explain why spa therapy is beneficial.

Principles for prescribing and starting an exercise program

Even in the face of evidence that supports the benefits of exercise, poor compliance with exercise recommendations is the biggest obstacle to having those benefits realised in the lives of individuals with FMS. In fact, it has been reported that 83% of individuals with FMS do not engage in aerobic exercise and the majority of those tested have below-average fitness levels. Shockingly, the average 40-year old with FMS has been found to be as physically unfit as an 80-year-old without the disorder^{101,102}! There are several physiologic reasons for the difficulties that someone with FMS must overcome in order to engage in and sustain an exercise program. Pain and fatigue are some of the biggest challenges and there are a several observations that might explain why these symptoms may be aggravated when someone with FMS begins an exercise program. Normally, exercise is thought to decrease pain because the body increases its production of endorphins (a natural analgesic) and activates the descending inhibitory pain pathways that blunt the impact of painful signals^{103,104}. There is evidence that special type of receptors in the brain called μ -opioid receptors that bind endorphins may be saturated in individuals with FMS making them less responsive to these natural analgesics¹⁰⁵.

As a result, pain may be felt more acutely. In addition, while muscle contraction in healthy individuals leads to inhibition of pain perception through the descending inhibitory pain pathways, this does not occur in individuals with FMS¹⁰⁶. Quite the opposite, a sustained muscle contraction in FMS results in an increased response to painful stimuli or hyperalgesia.

Abnormalities in the stress response system may also explain why exercise can be poorly tolerated in FMS. Low blood pressure, fatigue and orthostatic tachycardia, a rapid heart rate when suddenly assuming an upright position, are manifestations of this dysfunction. In addition, growth hormone, which is important for repair of muscle damage, does not increase as much in response to exercise in individuals with FMS¹⁰⁷. So muscles may feel sore for longer. And finally, when an individual's exercise program is in excess of what they can reasonably tolerate, the immune system produces chemicals called inflammatory cytokines that result in a 'sickness syndrome' leading to extreme fatigue^{108,109}.

Given these limitations, any exercise program that you may wish to undertake needs to be individualised to order to take into account the physiologic obstacles that you may be facing. One recommendation is that an exercise program should be undertaken only after several components of the medical management have been optimised such as education, nutrition, medications or supplements and after any co-existing medical conditions have been evaluated and treated. A general recommendation is that if you are a sedentary person with moderate to severe FMS, aerobics should be the last step in a progression of exercises. You may benefit more from starting with breathing exercises, posture and relaxation, followed by flexibility and then strength and endurance training¹¹⁰.

Finally, adopting a set of helpful principles before prescribing or starting an exercise program is likely to increase the chances of success of both sustaining the regimen and achieving your goals (see Table 6).

Table 6 - Ten principles for prescribing exercise in fibromyalgia ¹¹⁰.

Principles for prescribing exercise in fibromyalgia
1. Treat peripheral pain generators to minimise central sensitisation
2. Minimise eccentric muscle work i.e. muscle lengthening against resistance
3. Program low-intensity non-repetitive exercise
4. Recognise the importance of restorative sleep
5. Screen for and treat autonomic dysfunction
6. Evaluate for risk of poor balance and risks for falling
7. Modify exercise for common comorbidities (central sensitivity syndromes)
8. Address obesity and deconditioning
9. Conserve energy daily to exercise

○ Acupuncture



Acupuncture is one of the oldest forms of therapy in traditional Chinese medicine. Sharp, thin needles are inserted into the body at specific points such that the body's energy flow is adjusted and altered to flow in healthier patterns. Acupuncture has been used for a variety of illnesses and is widely used in the United States especially for pain relief ¹¹¹. The U.S. National Institute of Health (NIH) concluded that acupuncture could be a useful adjunct as part of a comprehensive management program for people with FMS¹¹².

Three randomised trials have investigated the effectiveness of acupuncture in FMS. In one study, acupuncture was added to the standard treatment of antidepressants and exercise in 58 women with FMS¹¹³. Acupuncture sessions were given twice weekly for a total of 20 sessions lasting 20 minutes. Three months following the end of treatment, those who received acupuncture had significant improvements in pain with a decreased number of tender points. However, these improvements were no longer evident at the 2-year mark suggesting that treatment may need to be repeated. Acupuncture treatments not only decreased pain, but also lead to greater improvement in fatigue and anxiety¹¹⁴, even when compared to treatment with an antidepressant¹¹⁵. Acupuncture appears to be a safe treatment for a number of symptoms associated with FMS. If acupuncture is something that you would like to consider, it is important to find a trained professional with experience in treating chronically painful disorders like FMS.

○ Psychological therapy



Emotional distress is often cited as one of the top six most common exacerbating factors of FMS symptoms¹¹⁶. Mental stress, worrying, chronic stress and emotional trauma are common triggers²⁷, along with psychological vulnerability to stress and a frightening stressful cultural environment¹¹⁷. A number of psychological treatment modalities have been shown to be beneficial in improving FMS symptoms, enhancing coping strategies and quality of life and should be an integral part of FMS management.

Cognitive-behavioural therapy

Cognitive-behavioural therapy (CBT) and operant-behavioural therapy (OBT) are two forms of psychotherapy that have been used to help manage FMS. CBT is a form of psychotherapy that focuses on changing negative emotions that lead to dysfunctional thinking and changing behaviour patterns that contribute to poor coping strategies. In general, the goal of CBT is to reduce negative emotions and pain perception while increasing self-efficacy, physical functioning and coping strategies. The aim of OBT is to reduce painful behaviour (that is often reinforced by other's reaction to the demonstration of pain) and to reinforce alternative, healthier behaviours. Physical exercise also tends to be a part of an operant learning program¹¹⁸. Randomised clinical trials have shown that CBT leads to improvements in coping with pain, reduces depressed moods and decreases health-care seeking behavior in individuals with FMS¹¹⁹. In this review, however, there appeared to be no significant effect of CBT on the pain itself, fatigue, sleep or health-related quality of life. In contrast, ten out of 14 randomized controlled trials evaluating CBT and OBT in the management of FMS did demonstrate significant improvement in measures of pain intensity, disability and mood with half of the studies reporting positive effects that were maintained at six months¹²⁰. Approximately half of the individuals reported at least a 50% reduction in pain, six to twenty-four months after therapy had been discontinued. How well people responded to therapy depended to some extent on the degree of physical and functional impairment before treatment. Those with lower levels of physical impairment before treatment responded the best, while those with high levels of physical impairment were actually at some risk of deteriorating after therapy¹²¹. This underscores the importance of ensuring that therapy is tailored to meet individual needs and that appropriate follow-up is carried out.

Cognitive Hypnotherapy

Cognitive hypnotherapy has been used for pain management in a number of disorders¹²². This approach typically involves hypnotic induction using suggestions for changes in perception, behaviour and coping. In addition, the individual is often taught how to use hypnosis to reduce pain throughout their daily life. In a Dutch randomised controlled trial, 40 individuals with FMS who received 8 one hour sessions of hypnotherapy for three months reported reduced pain intensity and fatigue and improvement in their sleep pattern, compared to those who received massage only¹²³. In a study comparing hypnotherapy to physical therapy, those individuals enrolled in hypnotherapy showed superior results in the areas of improved muscle pain, fatigue, sleep disturbance and their own overall assessment of the outcome¹²⁴. Hypnosis has also been shown to be superior to relaxation for the treatment of FMS pain¹²⁴. Guided imagery may also be useful in managing pain and anxiety¹²⁵, improving quality of life and reducing psychological symptoms¹²⁶. In spite of the limitations that have been identified in several studies¹²⁷, both hypnosis and guided imagery have been recommended as adjuncts to both pharmacological and non-pharmacological treatments in the guidelines put forth by the Association of Scientific Medical Societies of Germany¹²⁸.

Relaxation training

Relaxation training alone has not been shown to be as effective for pain reduction in FMS when compared to CBT, hypnotherapy, bath or massage therapy¹²⁹⁻¹³¹, though it is recommended as part of a multicomponent therapy. In terms of biofeedback, the results of studies are varied. Some studies describe benefits in terms of pain, depression and general quality of life¹³², while others report long-term improvement in sleep and depression (after two years), but no effect on pain¹³³. Both the American Pain Society and the Association of the Scientific Medical Societies of Germany do not recommend single therapy biofeedback.

Written emotional disclosure

Written emotional disclosure (ED) is a psychological intervention that has been shown to yield health benefits in several different populations including those with FMS. Initial studies in healthy college students found that those who were randomly assigned to disclose their deep thoughts and feelings about some personal trauma showed a drop in visits to the health center, decreased symptoms and improved psychological well-being^{134,135}. ED has also been shown to have detectable benefits on the immune system^{136,137}. Because surveys have shown that the rates of abuse, trauma and injury are higher in individuals with FMS¹³⁸, researchers have investigated whether written ED might be effective in reducing symptoms in this population. In a study in which 92 patients with FMS were randomised to a trauma-writing group, a control writing group or usual care, the trauma-writing group reported significant reductions in pain, fatigue and improved psychological well-being four months after the writing intervention¹³⁹. The writing groups wrote for 20 minutes, once a week for three weeks. At a 10-month follow-up, however, the benefits were not maintained suggesting that the writing intervention needs to be repeated and incorporated into a total model of care. It is also interesting that the improvements were not immediately visible. The emotional benefits did not surface until three to four months after the intervention. In fact, a negative mood tended to ensue immediately after the writing intervention. Guidelines from both the American Pain Society and the Association of the Scientific Medical Societies of Germany recommend writing interventions as an adjunct to CBT/OBT, exercise and pharmacotherapy.

You should be carefully evaluated before undergoing any form of psychological therapy, since the efficacy of a chosen treatment depends on a number of variables. For instance, individuals that are less physically impaired tend to respond well with decreasing pain to behavioural methods; while those with more severe physical impairment are more likely to have improvements in their overall level of physical impairment rather than in the area of pain. One study reported that those who report low pain intensity, high emotional distress and more physician visits, may even develop worse physical impairment after psychotherapy¹⁴⁰.

Pharmacological Management of FMS

As we have seen, the pathways involved in pain and other symptoms associated with FMS are complex. In considering the role of drug therapy, it is important to note that no single class of medication will work for everyone. The classes of drugs most commonly used include antidepressants, analgesics, anti-epileptic, muscle relaxants and sedatives/hypnotics.

Analgesics



Though non-steroidal anti-inflammatory drugs (NSAIDs) are among the most frequently used medications to treat FMS, there is little evidence that they are effective. Ibuprofen and naproxen, for instance, were found to be no more effective than placebo¹⁴¹. Nonetheless, in a survey of 1042 patients, 66.1% thought that NSAIDs were more effective than acetaminophen¹⁴². There is also some evidence that NSAIDs may be more effective when taken in combination with medications such as tricyclic antidepressants and anticonvulsants¹⁴³. One reason why NSAIDs and acetaminophen may be less effective is because they act primarily through mechanisms that don't really target central pain, but rather work peripherally.

Nevertheless, given the complex nature of FMS, there are still likely to be individuals with 'peripheral' components to their symptoms or who have other co-existing inflammatory conditions that would respond to NSAIDs or acetaminophen. The use of opiate analgesics is generally not recommended for the treatment of FMS^{10,12,144}. In addition to the limited number of randomised trials,¹⁴⁵ opiates have well known side-effects that include cognitive dysfunction, constipation, the development of tolerance requiring larger and larger doses and addiction. Opiates have been shown to increase pain sensitivity¹⁴⁶. Yet despite these observations, a recent survey with 2 596 respondents showed that hydrocodone and oxycodone preparations were among the most consistently used medications and were felt to be the most effective²⁷.

Tramadol is an analgesic with both opioid and antidepressant properties that is indicated for short-term management of pain (i.e. 5 days). It is also not a controlled substance. The most common side effects that limit how well it is tolerated, are nausea and skin rashes, though the nausea can be lessened when it is combined with acetaminophen¹⁴⁷.

It should also be used with caution with any other medications that lower the seizure threshold. Tramadol 's primary benefits have been in alleviating pain, improving sleep and physical function in individuals with FMS^{148,149}. Though it has been recommended by EULAR, it is not approved by the U.S. Federal Drug Administration (FDA) for treatment of FMS.

Antidepressants

There are currently two antidepressants approved by the U.S. FDA for the treatment of FMS: duloxetine and milnacipran. These antidepressants belong to the class of drugs called serotonin-norepinephrine reuptake inhibitors (SNRIs). Both medications have been shown in randomised, blinded, controlled trials to improve the pain associated with FMS¹⁵⁰. Duloxetine is often considered in patients with significant depression¹⁵¹ and milnacipran may be helpful when significant fatigue or cognitive dysfunction are present¹⁵². Nausea, insomnia, headaches are common side effects which may limit their use.

Amitriptyline has been shown to be most effective in terms of improving sleep quality, with modest improvement reported in stiffness and tenderness¹⁵³. Side effects such as sedation, dry mouth and constipation make it poorly tolerated at high doses so that smaller doses are often taken at bedtime. Further, when there is a history of heart, kidney or liver disease, it should be used with caution¹⁴⁷.

Anticonvulsants

Pregabalin is an anticonvulsant approved by the U.S. FDA for the treatment of FMS. In a double-blind placebo controlled trial, pregabalin effectively decreased pain¹⁵⁴, though it had significant side effects such as weight gain, dizziness, sleepiness or insomnia, swelling, nausea and anxiety.

Sedatives

Sodium oxybate is derived from a compound called gamma-hydroxybutyrate (GBH) that acts as a neurotransmitter that influences the activity of neurons in the central nervous system. It also stimulates the release of growth hormone. In randomised trials, sodium oxybate significantly improved sleep, pain and fatigue in FMS patients¹⁵⁵. In spite of these results, in 2010 it was not approved by U.S. FDA for treatment of FMS, primarily because of concerns about abuse. Common side effects include headache, nausea, dizziness and sleepiness.

Pharmacologic management of POTS

The U.S. FDA has not approved any specific drug for the management of POTS and there have not been any studies that have properly evaluated pharmacologic management. Medications such as, udrocortisone that help to correct low blood volume, propranolol that blunts the rapid increase in heart rate and midodrine that constricts blood vessels, have all been used. Octreotide is another class of medication that has been used in treating POTS¹⁵⁶, but side effects of abdominal pain and diarrhoea have limited its use. In general, about 40-60% of those treated with medications for PTOS experience improvement in their symptoms³⁸.

General principles of therapy

The main goal of therapy for individuals with FMS should be aimed at improving function, decreasing symptoms and fostering the development of healthy coping strategies for dealing constructively with a chronic illness. The choice of treatment options needs to be carefully reviewed by you and your provider and should be based on a clear understanding of the risks, benefits and costs. The results of a chosen comprehensive treatment approach need to be carefully monitored on a regular basis to ensure that the benefits outweigh the risks and that progress is being made. Many of the active treatments such as various forms of exercise, psychological support and dietary changes can be continued long term and in several cases have been proven to be superior to standard medical treatment¹¹. In some cases, the positive effects of these active treatments persist even after the end of therapy. In contrast, according to Association of the Scientific Medical Societies, evidence supporting the benefits of pharmacological agents has been mostly studied for up to six months. Therefore, the decision to continue medications should only be considered if you and your doctor see persistent benefits at regular check-ups¹¹ and consideration should be given to a drug holiday after six months¹⁵⁷.

Working with fibromyalgia



One of the common challenges and sources of stress for individuals with FMS surrounds the issue of work. If you are still in the work force, trying to balance the demands of the job with new physical limitations can be daunting. Feelings of isolation, frustration and hopelessness are not uncommon. This is where education both for the employee and employer can offer helpful guidelines¹⁵⁸. A first step is to get a clear assessment of the limitations that you are experiencing and how they affect your job performance. Consider discussing FMS with your employer and providing him/her with pamphlets to better acquaint them with the disorder.

A well-informed employer will usually be more willing to implement certain accommodations to fit your needs, many of which are simple and inexpensive. For example, a simple workstation analysis by an occupational therapist can establish good ergonomic habits that may ease symptoms.

- For office workers, adjustments can be made to the position of the keyboard, monitor and mouse on the computer. Chairs can be adjusted or new chairs purchased to ensure that your legs are at a 90-degree angle to the floor, and your arms at a 90-degree angle to the keyboard. Telephone headsets, anti-glare computer screens, portable angle writing surfaces, document holders and forearm supports for typing are just a few of the useful tools available.
- For individuals working in factories, a padded floor mat and a nearby stool, where periodic rests can be easily taken, can reduce fatigue. Also, using padded gloves can decrease excessive vibrations.
- For individuals with fine motor impairment, using built-up pens, light pressure pens, large calculators and light touch keyboards, may be of benefit. You should inquire about closer parking spaces, automatic door openers and the possibility of placing your workstation close to frequently used areas such as copiers, lunchrooms and restrooms.

You might also inquire about altering break schedules, flexible working hours and even working from home for part of the week. There are also a number of simple behavioural changes that you can adopt to help alleviate symptoms in the workplace. Giving your body a break by taking time for walking and stretching to alleviate muscle strain and pacing yourself by switching between large and small tasks are two simple adjustments that can have enormous benefits.

Being diagnosed with FMS can also present an opportunity to re-evaluate your situation and consider a complete career change. As one author stated after realising that chronic pain had derailed her career aspirations in academia, “The first step is to accept your current circumstances rather than torturing yourself with comparisons of where you once were and would have liked to be... Acceptance can be liberating “¹⁵⁹. Focusing on what you *are* able to do and exploring things that you enjoy will often lead to new opportunities. Some general guidelines are to look for work that is meaningful to you, low stress, flexible and comfortable. Sources such as online searches, friends, previous colleagues, libraries and self-help books can provide a wealth of information. Professionals such as occupational therapists can suggest adaptive changes that may be needed in your work environment and career counsellors and life coaches can help you to evaluate different options and offer support. With the technology available today, many fields such as consulting work, online businesses and freelance work can be managed from home.

Online interventions in fibromyalgia



The use of modern information technology in the area of health-care has made it possible to deliver a number of innovative strategies for designing interventions that provide education, support and interactive services to individual patients. These services cannot only delivered through home computers, but also through tablets and smart phones. Though a review of online FMS resources concluded that most were of low quality and failed to provide accurate, comprehensive information¹⁶⁰, there have been a few projects that have yielded useful information.

In 2008, an internet-based adaptation of the Arthritis Self-Management Program (ASMP), designed for patients who could not attend small groups, was evaluated and found to be effective in changing health-related behaviours¹⁶¹. Though primarily geared towards patients with arthritis, patients with FMS also participated. The program included education on symptoms, fatigue management, doctor-patient communication and problem solving and required participants to log in at least three times for a total of one to two hours. Several other reviews of online programs that have targeted patients with rheumatoid arthritis, osteoarthritis and FMS have reported that participants had improvements in pain, global health, physical functioning and self-efficacy¹⁶²⁻¹⁶⁴. In 2012, an internet-based intervention for people with FMS was developed, called “SMARTLog” or SMART self-monitoring and review tool. Participants logged in to record daily activities, health-related behaviors, stressors and symptom levels. This information was then used to build a personal database. Data was then analysed in order to identify which personal behaviours predicted changes in symptom levels and this information was shared with the participant. Individuals who participated at least three to 4.5 times per week, over three to five months had significant improvements in pain, memory, gastrointestinal problems, depression, fatigue and concentration¹⁶⁴.

The SMARTLog program should be available in the near future at www.collinge.org. These programs are likely to become increasingly popular if they continue to demonstrate effectiveness and patient satisfaction. Fibromyalgia syndrome is a complex, debilitating disorder that affects millions of people worldwide. In addition to its impact on individual quality of life, nations are becoming increasingly aware of the staggering healthcare costs and loss of productivity associated with this disorder. Over the years, research has begun to shed light on some of the factors that may be underlying FMS symptoms and we are gaining a greater appreciation of the benefits that various non-pharmacologic and pharmacologic treatments and therapies have to offer.

The approach to treatment should entail careful individual evaluation and should encourage your active participation in designing a comprehensive plan. The guidelines put forth by the Association of the Scientific Medical Societies of Germany can provide a good source of information regarding the wide range of treatment options that are likely to be effective (Tables 7-9). Finally, there is increasing recognition that simple changes can be made in the workplace to address any number of potential limitations that you may be facing. And while a career change is always an option, you and your employer both should freely consult professional sources for information on a wide array of inexpensive adaptations that can be easily incorporated into the work environment. Information technology may be providing innovative, effective and easily accessible programs with the potential to yield measurable benefits for those coping with FMS.

Table 7 - Treatments with strong recommendations for the management of adult fibromyalgia syndrome

Therapy	Strength of consensus
Patient education	
Information on diagnosis and therapeutic options	Strong
Patient education within multicomponent therapy	Strong
Patient-centered communication	Strong
Exercise	
Aerobic exercise	Strong
Psychotherapy	
Cognitive-behavioral therapy (CBT)	Strong
Multicomponent therapy	
Multicomponent therapy	Strong
Pharmacological therapy	
Amitriptyline	Strong

Table 8 - Recommended treatments for the management of adult fibromyalgia syndrome

Therapy	Strength of consensus
Physiotherapy and physical therapy	
Balneo- and spa therapy	Strong
Whole body heat	Strong
Psychotherapy	
Hypnotherapy/guided imagery	Consensus
Written emotional disclosure (ED)	Strong
Pharmacological therapy	
Fluoxetine	Strong
Paroxetine	Strong
Duloxetine	Strong

Table 9 - Treatments with open recommendations for the management of adult fibromyalgia syndrome

Therapy	Strength of consensus
Physiotherapy and physical therapy	
Whole body cold therapy	Consensus
Low energy laser	Consensus
Magnet field therapy	Consensus
Ultrasounds and electrotherapy	Consensus
Lymph drainage	Consensus
Osteopathy	Consensus
Transcranial magnet stimulation	Consensus
Physiotherapy	Consensus
Functional training	Strong
Occupational therapy as part of multicomponent therapy	Majority
Psychotherapy	
Relaxation training as part of multicomponent therapy	Strong
Psychodynamic therapy	Majority
Pharmacological therapy	
Cyclobenzaprine	Strong
Sertraline	Strong
Tramadol or Tramadol/Aminoacetophen	Strong
Pregabalin	Strong
Tropisetron	Consensus
Pramiprexol	Consensus
Complementary and alternative therapies	
Homeopathy	Consensus
Vegetarian diet	Consensus
Elimination diet	Consensus
Acupuncture as part of multicomponent therapy	Consensus
Tai-Chi, Qi-Gong as part of multicomponent therapy	Strong
Music therapy as part of multicomponent therapy	Strong
Body therapies (Body-awareness, Feldenkrais, music therapy) as part of multicomponent therapy	Strong

Resources

National Fibromyalgia Association (NFA)-non-profit
 2121 S Towne Centre Place Suite 300
 Anaheim, CA 92806-0150
 FMaware.org

European Network of Fibromyalgia Associations (ENFA)
 President Robert Boelhouwer
 Email fes.fesinfo.nl

Collinge and Associates
 Innovation, consultation and research in integrative health care
 www.collinge.org.

Glossary of terms

Adrenal insufficiency: a condition where the adrenal glands that are located above the kidneys do not produce enough steroid hormones.

Central nervous system: part of the nervous system that consists of the brain and spinal cord.

Cerebral spinal fluid: a clear fluid that surrounds the brain and spinal cord.

Cortisol: a hormone that is made in the adrenal glands

Double-blind trial: an experimental study in which neither the individuals participating in the experiment nor the person administering the intervention know which intervention is being evaluated i.e. a placebo versus a medication.

Glial cells: cells in the nervous system that surround nerve cells or neurons and have a supportive and protective function. Unlike neurons, they do not conduct electrical impulses.

Growth Hormone: a hormone secreted by the pituitary gland that promotes growth, cell reproduction and regeneration.

HPA-hypothalamic-pituitary-axis: a network that includes the hypothalamus and pituitary located in the brain and the adrenals, located above the kidneys, that regulates a complex network of hormonal activity.

Hypothyroidism: a condition in which the thyroid gland does not make enough thyroid hormone.
Interstitial cystitis: long term inflammation of the bladder wall.

Mitochondria: structures located within cells that provide the energy the cell requires in order to carry out its many functions.

Norepinephrine: also known as noradrenaline, is a hormone and neurotransmitter that is important in the 'fight or flight response' and affects many aspects of the cardiovascular system.

Neurotransmitters: chemicals that transmit signals from neurons to other cells in the body.

Peripheral nervous system: part of the nervous system that lies outside of the brain and spinal cord.

Prostatitis: inflammation of the prostate gland.

Serotonin: also known as 5-hydroxytryptamine is a neurotransmitter that is found in the gastrointestinal tract, blood cells called platelets and in the central nervous system.

Sympathetic nervous system: one part of the autonomic nervous system (the involuntary nervous system) that regulates the 'fight or flight response' and is important for maintaining homeostasis.

REFERENCES

1. Weir PT, Harlan GA, Nkoy FL, et al. The incidence of fibromyalgia and its associated comorbidities: a population-based retrospective cohort study based on International Classification of Diseases, 9th Revision codes. *Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases*. Jun 2006;12(3):124-128.
2. Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. *Arthritis and rheumatism*. May 1998;41(5):778-799.
3. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. *Arthritis and rheumatism*. Jan 1995;38(1):19-28.
4. White KP, Speechley M, Harth M, Ostbye T. The London Fibromyalgia Epidemiology Study: comparing the demographic and clinical characteristics in 100 random community cases of fibromyalgia versus controls. *The Journal of rheumatology*. Jul 1999;26(7):1577-1585.
5. White KP, Harth M. Classification, epidemiology, and natural history of fibromyalgia. *Current pain and headache reports*. Aug 2001;5(4):320-329.
6. Kasman NM, Badley EM. Beyond access: who reports that health care is not being received when needed in a publicly-funded health care system? *Canadian journal of public health. Revue canadienne de sante publique*. Jul-Aug 2004;95(4):304-308.
7. Wolfe F, Anderson J, Harkness D, et al. A prospective, longitudinal, multicenter study of service utilization and costs in fibromyalgia. *Arthritis and rheumatism*. Sep 1997;40(9):1560-1570.
8. Marschall U, Arnold B, Hauser W. [Treatment and healthcare costs of fibromyalgia syndrome in Germany: analysis of the data of the Barmer health insurance (BEK) from 2008-2009]. *Schmerz*. Aug 2011;25(4):402-404, 406-410.
9. Buckhardt CS GD, Crofford L, Gerwin R, Gowens S, Jackson K, Kugel P, McCarberg W, Rudin N, Schanberg L, Taylor AG, Taylor J, Turk D. Guideline for the management of fibromyalgia syndrome pain in adults and children. *Glenview (IL): American Pain Society (APS); (Clinical practice guideline; no. 4)*. . 2005.
10. Carville SF, Arendt-Nielsen S, Bliddal H, et al. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. *Annals of the rheumatic diseases*. Apr 2008;67(4):536-541.
11. Hauser W, Arnold B, Eich W, et al. Management of fibromyalgia syndrome--an interdisciplinary evidence-based guideline. *German medical science : GMS e-journal*. 2008;6:Doc14.
12. Hauser W, Thieme K, Turk DC. Guidelines on the management of fibromyalgia syndrome - a systematic review. *Eur J Pain*. Jan 2010;14(1):5-10.
13. Felson DT. Comparing the prevalence of rheumatic diseases in China with the rest of the world. *Arthritis research & therapy*. 2008;10(1):106.
14. Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. *Arthritis and rheumatism*. Jan 2008;58(1):26-35.
15. Greenfield S, Fitzcharles MA, Esdaile JM. Reactive fibromyalgia syndrome. *Arthritis and rheumatism*. Jun 1992;35(6):678-681.
16. Giesecke T, Williams DA, Harris RE, et al. Subgrouping of fibromyalgia patients on the basis of pressure-pain thresholds and psychological factors. *Arthritis and rheumatism*. Oct 2003;48(10):2916-2922.
17. Clauw DJ, Crofford LJ. Chronic widespread pain and fibromyalgia: what we know, and what we need to know. *Best practice & research. Clinical rheumatology*. Aug 2003;17(4):685-701.
18. McBeth J, Macfarlane GJ, Benjamin S, Silman AJ. Features of somatization predict the onset of chronic widespread pain: results of a large population-based study. *Arthritis and rheumatism*. Apr 2001;44(4):940-946.
19. Cohen H, Neumann L, Haiman Y, Matar MA, Press J, Buskila D. Prevalence of post-traumatic stress disorder in fibromyalgia patients: overlapping syndromes or post-traumatic fibromyalgia syndrome? *Seminars in arthritis and rheumatism*. Aug 2002;32(1):38-50.
20. Epstein SA, Kay G, Clauw D, et al. Psychiatric disorders in patients with fibromyalgia. A multicenter investigation. *Psychosomatics*. Jan-Feb 1999;40(1):57-63.
21. Nash P, Chard M, Hazleman B. Chronic coxsackie B infection mimicking primary fibromyalgia. *The Journal of rheumatology*. Nov 1989;16(11):1506-1508.
22. Leventhal LJ, Naides SJ, Freundlich B. Fibromyalgia and parvovirus infection. *Arthritis and rheumatism*. Oct 1991;34(10):1319-1324.
23. Dinerman H, Steere AC. Lyme disease associated with fibromyalgia. *Annals of internal medicine*. Aug 15 1992;117(4):281-285.
24. Ablin JN, Shoenfeld Y, Buskila D. Fibromyalgia, infection and vaccination: two more parts in the etiological puzzle. *Journal of autoimmunity*. Nov 2006;27(3):145-152.
25. Buskila D, Atzeni F, Sarzi-Puttini P. Etiology of fibromyalgia: the possible role of infection and vaccination. *Autoimmunity reviews*. Oct 2008;8(1):41-43.
26. Waylonis GW, Perkins RH. Post-traumatic fibromyalgia. A long-term follow-up. *American journal of physical medicine & rehabilitation / Association of Academic Physiatrists*. Nov-Dec 1994;73(6):403-412.

27. Bennett RM, Jones J, Turk DC, Russell IJ, Matallana L. An internet survey of 2,596 people with fibromyalgia. *BMC musculoskeletal disorders*. 2007;8:27.
28. Bell IR, Baldwin CM, Schwartz GE. Illness from low levels of environmental chemicals: relevance to chronic fatigue syndrome and fibromyalgia. *The American journal of medicine*. Sep 28 1998;105(3A):74S-82S.
29. Arnold LM, Hudson JI, Hess EV, et al. Family study of fibromyalgia. *Arthritis and rheumatism*. Mar 2004;50(3):944-952.
30. Wolfe F, Clauw DJ, Fitzcharles MA, et al. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia. *The Journal of rheumatology*. Jun 2011;38(6):1113-1122.
31. Schneider MJ, Brady DM, Perle SM. Commentary: differential diagnosis of fibromyalgia syndrome: proposal of a model and algorithm for patients presenting with the primary symptom of chronic widespread pain. *Journal of manipulative and physiological therapeutics*. Jul-Aug 2006;29(6):493-501.
32. Williams DA, Clauw DJ. Understanding fibromyalgia: lessons from the broader pain research community. *The journal of pain : official journal of the American Pain Society*. Aug 2009;10(8):777-791.
33. Marques AP, Ferreira EA, Matsutani LA, Pereira CA, Assumpcao A. Quantifying pain threshold and quality of life of fibromyalgia patients. *Clinical rheumatology*. Jun 2005;24(3):266-271.
34. Ablin K, Clauw DJ. From fibrositis to functional somatic syndromes to a bell-shaped curve of pain and sensory sensitivity: evolution of a clinical construct. *Rheumatic diseases clinics of North America*. May 2009;35(2):233-251.
35. Gracely RH, Petzke F, Wolf JM, Clauw DJ. Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. *Arthritis and rheumatism*. May 2002;46(5):1333-1343.
36. Russell IJ, Larson AA. Neurophysiopathogenesis of fibromyalgia syndrome: a unified hypothesis. *Rheumatic diseases clinics of North America*. May 2009;35(2):421-435.
37. Russell IJ, Vaeroy H, Javors M, Nyberg F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. *Arthritis and rheumatism*. May 1992;35(5):550-556.
38. Staud R. Autonomic dysfunction in fibromyalgia syndrome: postural orthostatic tachycardia. *Current rheumatology reports*. Dec 2008;10(6):463-466.
39. Ferraccioli G, Cavalieri F, Salaffi F, et al. Neuroendocrinologic findings in primary fibromyalgia (soft tissue chronic pain syndrome) and in other chronic rheumatic conditions (rheumatoid arthritis, low back pain). *The Journal of rheumatology*. Jul 1990;17(7):869-873.
40. McCain GA, Tilbe KS. Diurnal hormone variation in fibromyalgia syndrome: a comparison with rheumatoid arthritis. *The Journal of rheumatology*. Supplement. Nov 1989;19:154-157.
41. Crofford LJ, Young EA, Engleberg NC, et al. Basal circadian and pulsatile ACTH and cortisol secretion in patients with fibromyalgia and/or chronic fatigue syndrome. *Brain, behavior, and immunity*. Jul 2004;18(4):314-325.
42. Van Cauter E, Plat L, Copinschi G. Interrelations between sleep and the somatotrophic axis. *Sleep*. Sep 15 1998;21(6):553-566.
43. Kim SH. Skin biopsy findings: implications for the pathophysiology of fibromyalgia. *Medical hypotheses*. 2007;69(1):141-144.
44. Ozgocmen S, Ozyurt H, Sogut S, Akyol O, Ardicoglu O, Yildizhan H. Antioxidant status, lipid peroxidation and nitric oxide in fibromyalgia: etiologic and therapeutic concerns. *Rheumatology international*. May 2006;26(7):598-603.
45. Bagis S, Tamer L, Sahin G, et al. Free radicals and antioxidants in primary fibromyalgia: an oxidative stress disorder? *Rheumatology international*. Apr 2005;25(3):188-190.
46. Wallace DJ, Linker-Israeli M, Hallegua D, Silverman S, Silver D, Weisman MH. Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study. *Rheumatology (Oxford)*. Jul 2001;40(7):743-749.
47. Eisinger J, Plantamura A, Marie PA, Ayavou T. Selenium and magnesium status in fibromyalgia. *Magnesium research : official organ of the International Society for the Development of Research on Magnesium*. Dec 1994;7(3-4):285-288.
48. Reinhard P, Schweinsberg F, Wernet D, Kotter I. Selenium status in fibromyalgia. *Toxicology letters*. Aug 1998;96-97:177-180.
49. Zhang Z, Cherryholmes G, Mao A, et al. High plasma levels of MCP-1 and eotaxin provide evidence for an immunological basis of fibromyalgia. *Exp Biol Med (Maywood)*. Sep 2008;233(9):1171-1180.
50. Staud R. Abnormal pain modulation in patients with spatially distributed chronic pain: fibromyalgia. *Rheumatic diseases clinics of North America*. May 2009;35(2):263-274.
51. Offenbaecher M, Bondy B, de Jonge S, et al. Possible association of fibromyalgia with a polymorphism in the serotonin transporter gene regulatory region. *Arthritis and rheumatism*. Nov 1999;42(11):2482-2488.
52. Cohen H, Buskila D, Neumann L, Ebstein RP. Confirmation of an association between fibromyalgia and serotonin transporter promoter region (5-HTTLPR) polymorphism, and relationship to anxiety-related personality traits. *Arthritis and rheumatism*. Mar 2002;46(3):845-847.
53. Buskila D, Cohen H, Neumann L, Ebstein RP. An association between fibromyalgia and the dopamine D4 receptor exon III repeat polymorphism and relationship to novelty seeking personality traits. *Molecular psychiatry*. Aug 2004;9(8):730-731.
54. Gursoy S, Erdal E, Herken H, Madenci E, Alasehirli B, Erdal N. Significance of catechol-O-methyltransferase gene polymorphism in fibromyalgia syndrome. *Rheumatology international*. May 2003;23(3):104-107.
55. Zubieta JK, Heitzeg MM, Smith YR, et al. COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. *Science*. Feb 21 2003;299(5610):1240-1243.

56. Mease P. Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment. *The Journal of rheumatology*. Supplement. Aug 2005;75:6-21.
57. Benditt DG, Sutton R. Tilt-table testing in the evaluation of syncope. *Journal of cardiovascular electrophysiology*. Mar 2005;16(3):356-358.
58. Leavitt F, Katz RS. Distraction as a key determinant of impaired memory in patients with fibromyalgia. *The Journal of rheumatology*. Jan 2006;33(1):127-132.
59. Leavitt F, Katz RS. Speed of mental operations in fibromyalgia: a selective naming speed deficit. *Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases*. Aug 2008;14(4):214-218.
60. Rooks DS, Gautam S, Romeling M, et al. Group exercise, education, and combination self-management in women with fibromyalgia: a randomized trial. *Archives of internal medicine*. Nov 12 2007;167(20):2192-2200.
61. Mengshoel AM, Heggen K. Recovery from fibromyalgia - previous patients' own experiences. *Disability and rehabilitation*. Jan 7 2004;26(1):46-53.
62. McCracken LM, Vowles KE, Eccleston C. Acceptance-based treatment for persons with complex, long standing chronic pain: a preliminary analysis of treatment outcome in comparison to a waiting phase. *Behaviour research and therapy*. Oct 2005;43(10):1335-1346.
63. Arranz LI, Canela MA, Rafecas M. Dietary aspects in fibromyalgia patients: results of a survey on food awareness, allergies, and nutritional supplementation. *Rheumatology international*. Sep 2012;32(9):2615-2621.
64. Neumann L, Lerner E, Glazer Y, Bolotin A, Shefer A, Buskila D. A cross-sectional study of the relationship between body mass index and clinical characteristics, tenderness measures, quality of life, and physical functioning in fibromyalgia patients. *Clinical rheumatology*. Dec 2008;27(12):1543-1547.
65. Hanninen, Kaartinen K, Rauma AL, et al. Antioxidants in vegan diet and rheumatic disorders. *Toxicology*. Nov 30 2000;155(1-3):45-53.
66. Donaldson MS, Speight N, Loomis S. Fibromyalgia syndrome improved using a mostly raw vegetarian diet: an observational study. *BMC complementary and alternative medicine*. 2001;1:7.
67. Azad KA, Alam MN, Haq SA, et al. Vegetarian diet in the treatment of fibromyalgia. *Bangladesh Medical Research Council bulletin*. Aug 2000;26(2):41-47.
68. Smith JD, Terpening CM, Schmidt SO, Gums JG. Relief of fibromyalgia symptoms following discontinuation of dietary excitotoxins. *The Annals of pharmacotherapy*. Jun 2001;35(6):702-706.
69. Al-Allaf AW, Mole PA, Paterson CR, Pullar T. Bone health in patients with fibromyalgia. *Rheumatology (Oxford)*. Oct 2003;42(10):1202-1206.
70. Block SR. Vitamin D deficiency is not associated with nonspecific musculoskeletal pain syndromes including fibromyalgia. *Mayo Clinic proceedings*. Mayo Clinic. Dec 2004;79(12):1585-1586; author reply 1586-1587.
71. Sendur OF, Tastaban E, Turan Y, Ulman C. The relationship between serum trace element levels and clinical parameters in patients with fibromyalgia. *Rheumatology international*. Sep 2008;28(11):1117-1121.
72. Rosborg I, Hyllen E, Lidbeck J, Nihlgard B, Gerhardsson L. Trace element pattern in patients with fibromyalgia. *The Science of the total environment*. Oct 15 2007;385(1-3):20-27.
73. Altindag O, Celik H. Total antioxidant capacity and the severity of the pain in patients with fibromyalgia. *Redox report : communications in free radical research*. 2006;11(3):131-135.
74. Rohr UD, Herold J. Melatonin deficiencies in women. *Maturitas*. Apr 15 2002;41 Suppl 1:S85-104.
75. Sarzi Puttini P, Caruso I. Primary fibromyalgia syndrome and 5-hydroxy-L-tryptophan: a 90-day open study. *The Journal of international medical research*. Apr 1992;20(2):182-189.
76. Nicolodi M, Sicuteri F. Fibromyalgia and migraine, two faces of the same mechanism. Serotonin as the common clue for pathogenesis and therapy. *Advances in experimental medicine and biology*. 1996;398:373-379.
77. Birdsall TC. 5-Hydroxytryptophan: a clinically-effective serotonin precursor. *Alternative medicine review : a journal of clinical therapeutic*. Aug 1998;3(4):271-280.
78. Caruso I, Sarzi Puttini P, Cazzola M, Azzolini V. Double-blind study of 5-hydroxytryptophan versus placebo in the treatment of primary fibromyalgia syndrome. *The Journal of international medical research*. May-Jun 1990;18(3):201-209.
79. Merchant RE, Andre CA. A review of recent clinical trials of the nutritional supplement *Chlorella pyrenoidosa* in the treatment of fibromyalgia, hypertension, and ulcerative colitis. *Alternative therapies in health and medicine*. May-Jun 2001;7(3):79-91.
80. Rossini M, Di Munno O, Valentini G, et al. Double-blind, multicenter trial comparing acetyl L-carnitine with placebo in the treatment of fibromyalgia patients. *Clinical and experimental rheumatology*. Mar-Apr 2007;25(2):182-188.
81. Russell IJ, Michalek JE, Flechas JD, Abraham GE. Treatment of fibromyalgia syndrome with Super Malic: a randomized, double blind, placebo controlled, crossover pilot study. *The Journal of rheumatology*. May 1995;22(5):953-958.
82. Tavoni A, Vitali C, Bombardieri S, Pasero G. Evaluation of S-adenosylmethionine in primary fibromyalgia. A double-blind crossover study. *The American journal of medicine*. Nov 20 1987;83(5A):107-110.
83. Tavoni A, Jeracitano G, Cirigliano G. Evaluation of S-adenosylmethionine in secondary fibromyalgia: a double-blind study. *Clinical and experimental rheumatology*. Jan-Feb 1998;16(1):106-107.

- 84.**Jacobsen S, Danneskiold-Samsøe B, Andersen RB. Oral S-adenosylmethionine in primary fibromyalgia. Double-blind clinical evaluation. *Scandinavian journal of rheumatology*. 1991;20(4):294-302.
- 85.**Volkman H, Norregaard J, Jacobsen S, Danneskiold-Samsøe B, Knoke G, Nehrlich D. Double-blind, placebo-controlled cross-over study of intravenous S-adenosyl-L-methionine in patients with fibromyalgia. *Scandinavian journal of rheumatology*. 1997;26(3):206-211.
- 86.**Lister RE. An open, pilot study to evaluate the potential benefits of coenzyme Q10 combined with Ginkgo biloba extract in fibromyalgia syndrome. *The Journal of international medical research*. Mar-Apr 2002;30(2):195-199.
- 87.**Olson GB, Savage S, Olson J. The effects of collagen hydrolysate on symptoms of chronic fibromyalgia and temporomandibular joint pain. *Cranio : the journal of craniomandibular practice*. Apr 2000;18(2):135-141.
- 88.**Bramwell B, Ferguson S, Scarlett N, Macintosh A. The use of ascorbigen in the treatment of fibromyalgia patients: a preliminary trial. *Alternative medicine review : a journal of clinical therapeutic*. Oct 2000;5(5):455-462.
- 89.**Fetrow CW, Avila JR. Efficacy of the dietary supplement S-adenosyl-L-methionine. *The Annals of pharmacotherapy*. Nov 2001;35(11):1414-1425.
- 90.**Casanueva B, Rodero B, Quintal C, Llorca J, Gonzalez-Gay MA. Short-term efficacy of topical capsaicin therapy in severely affected fibromyalgia patients. *Rheumatology international*. Jul 28 2012.
- 91.**Teitelbaum JE, Johnson C, St. Cyr JS. The use of D-ribose in chronic fatigue syndrome and fibromyalgia: a pilot study. *Journal of Alternative & Complementary Medicine*. 2006;12(9):857-862.
- 92.**Hauser W, Klose P, Langhorst J, et al. Efficacy of different types of aerobic exercise in fibromyalgia syndrome: a systematic review and meta-analysis of randomised controlled trials. *Arthritis research & therapy*. 2010;12(3):R79.
- 93.**Sanudo B, Galiano D, Carrasco L, de Hoyo M, McVeigh JG. Effects of a prolonged exercise program on key health outcomes in women with fibromyalgia: a randomized controlled trial. *Journal of rehabilitation medicine : official journal of the UEMS European Board of Physical and Rehabilitation Medicine*. May 2011;43(6):521-526.
- 94.**Wang C, Roubenoff R, Lau J, et al. Effect of Tai Chi in adults with rheumatoid arthritis. *Rheumatology (Oxford)*. May 2005;44(5):685-687.
- 95.**Jones KD, Sherman CA, Mist SD, Carson JW, Bennett RM, Li F. A randomized controlled trial of 8-form Tai chi improves symptoms and functional mobility in fibromyalgia patients. *Clinical rheumatology*. Aug 2012;31(8):1205-1214.
- 96.**Li F, Harmer P, Fitzgerald K, et al. Tai chi and postural stability in patients with Parkinson's disease. *The New England journal of medicine*. Feb 9 2012;366(6):511-519.
- 97.**Yap SY HC. *Chaoyi Fanhuan Qigong Healing*. iUniverse, Inc. New York. 2009.
- 98.**Lynch M, Sawynok J, Hiew C, Marcon D. A randomized controlled trial of qigong for fibromyalgia. *Arthritis research & therapy*. Aug 3 2012;14(4):R178.
- 99.**Sukenik S, Flusser D, Abu-Shakra M. The role of spa therapy in various rheumatic diseases. *Rheumatic diseases clinics of North America*. Nov 1999;25(4):883-897.
- 100.**McVeigh JG, McGaughey H, Hall M, Kane P. The effectiveness of hydrotherapy in the management of fibromyalgia syndrome: a systematic review. *Rheumatology international*. Dec 2008;29(2):119-130.
- 101.**Rutledge DN, Jones K, Jones CJ. Predicting high physical function in people with fibromyalgia. *Journal of nursing scholarship : an official publication of Sigma Theta Tau International Honor Society of Nursing / Sigma Theta Tau*. 2007;39(4):319-324.
- 102.**Shillam CR, Dupree Jones K, Miller L. Fibromyalgia symptoms, physical function, and comorbidity in middle-aged and older adults. *Nursing research*. Sep-Oct 2011;60(5):309-317.
- 103.**Goldfarb AH, Jamurtas AZ. Beta-endorphin response to exercise. An update. *Sports Med*. Jul 1997;24(1):8-16.
- 104.**Carrasco L, Villaverde C, Oltras CM. Endorphin responses to stress induced by competitive swimming event. *The Journal of sports medicine and physical fitness*. Jun 2007;47(2):239-245.
- 105.**Harris RE, Clauw DJ, Scott DJ, McLean SA, Gracely RH, Zubieta JK. Decreased central mu-opioid receptor availability in fibromyalgia. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. Sep 12 2007;27(37):10000-10006.
- 106.**Staud R, Robinson ME, Price DD. Isometric exercise has opposite effects on central pain mechanisms in fibromyalgia patients compared to normal controls. *Pain*. Nov 2005;118(1-2):176-184.
- 107.**Bennett R. Growth hormone in musculoskeletal pain states. *Current rheumatology reports*. Aug 2004;6(4):266-273.
- 108.**Suzuki K, Nakaji S, Yamada M, Totsuka M, Sato K, Sugawara K. Systemic inflammatory response to exhaustive exercise. *Cytokine kinetics. Exercise immunology review*. 2002;8:6-48.
- 109.**Dantzer R, Kelley KW. Twenty years of research on cytokine-induced sickness behavior. *Brain, behavior, and immunity*. Feb 2007;21(2):153-160.
- 110.**Jones KD, Liptan GL. Exercise interventions in fibromyalgia: clinical applications from the evidence. *Rheumatic diseases clinics of North America*. May 2009;35(2):373-391.
- 111.**Ezzo J, Berman B, Hadhazy VA, Jadad AR, Lao L, Singh BB. Is acupuncture effective for the treatment of chronic pain? A systematic review. *Pain*. Jun 2000;86(3):217-225.
- 112.**NIH Consensus Conference. Acupuncture. *JAMA : the journal of the American Medical Association*. Nov 4 1998;280(17):1518-1524.

- 113.**Targino RA, Imamura M, Kaziyama HH, et al. A randomized controlled trial of acupuncture added to usual treatment for fibromyalgia. *Journal of rehabilitation medicine : official journal of the UEMS European Board of Physical and Rehabilitation Medicine*. Jul 2008;40(7):582-588.
- 114.**Martin DP, Sletten CD, Williams BA, Berger IH. Improvement in fibromyalgia symptoms with acupuncture: results of a randomized controlled trial. *Mayo Clinic proceedings. Mayo Clinic*. Jun 2006;81(6):749-757.
- 115.**Hadianfard MJ, Hosseinzadeh Parizi M. A randomized clinical trial of fibromyalgia treatment with acupuncture compared with fluoxetine. *Iranian Red Crescent medical journal*. Oct 2012;14(10):631-640.
- 116.**Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. *Arthritis and rheumatism*. Feb 1990;33(2):160-172.
- 117.**Winfield JB. Psychological determinants of fibromyalgia and related syndromes. *Current review of pain*. 2000;4(4):276-286.
- 118.**Thieme K, Gromnica-Ihle E, Flor H. Operant behavioral treatment of fibromyalgia: a controlled study. *Arthritis and rheumatism*. Jun 15 2003;49(3):314-320.
- 119.**Bernardy K, Fuber N, Kollner V, Hauser W. Efficacy of cognitive-behavioral therapies in fibromyalgia syndrome - a systematic review and metaanalysis of randomized controlled trials. *The Journal of rheumatology*. Oct 2010;37(10):1991-2005.
- 120.**Thieme K, Gracely RH. Are psychological treatments effective for fibromyalgia pain? *Current rheumatology reports*. Dec 2009;11(6):443-450.
- 121.**Thieme K, Turk DC, Flor H. Responder criteria for operant and cognitive-behavioral treatment of fibromyalgia syndrome. *Arthritis and rheumatism*. Jun 15 2007;57(5):830-836.
- 122.**Elkins G, Johnson A, Fisher W. Cognitive hypnotherapy for pain management. *The American journal of clinical hypnosis*. Apr 2012;54(4):294-310.
- 123.**Haanen HC, Hoenderdos HT, van Romunde LK, et al. Controlled trial of hypnotherapy in the treatment of refractory fibromyalgia. *The Journal of rheumatology*. Jan 1991;18(1):72-75.
- 124.**Castel A, Perez M, Sala J, Padrol A, Rull M. Effect of hypnotic suggestion on fibromyalgic pain: comparison between hypnosis and relaxation. *Eur J Pain*. May 2007;11(4):463-468.
- 125.**Fors EA, Sexton H, Gotestam KG. The effect of guided imagery and amitriptyline on daily fibromyalgia pain: a prospective, randomized, controlled trial. *Journal of psychiatric research*. May-Jun 2002;36(3):179-187.
- 126.**Menzies V, Taylor AG, Bourguignon C. Effects of guided imagery on outcomes of pain, functional status, and self-efficacy in persons diagnosed with fibromyalgia. *J Altern Complement Med*. Jan-Feb 2006;12(1):23-30.
- 127.**Bernardy K, Fuber N, Klose P, Hauser W. Efficacy of hypnosis/guided imagery in fibromyalgia syndrome--a systematic review and meta-analysis of controlled trials. *BMC musculoskeletal disorders*. 2011;12:133.
- 128.**Thieme K, Hauser W, Batra A, et al. [Psychotherapy in patients with fibromyalgia syndrome]. *Schmerz*. Jun 2008;22(3):295-302.
- 129.**Field T, Diego M, Cullen C, Hernandez-Reif M, Sunshine W, Douglas S. Fibromyalgia pain and substance P decrease and sleep improves after massage therapy. *Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases*. Apr 2002;8(2):72-76.
- 130.**Hammond A, Freeman K. Community patient education and exercise for people with fibromyalgia: a parallel group randomized controlled trial. *Clinical rehabilitation*. Oct 2006;20(10):835-846.
- 131.**Rucco V, Feruglio C, Genco F, Mosanghini R. [Autogenic training versus Erickson's analogical technique in treatment of fibromyalgia syndrome]. *Rivista europea per le scienze mediche e farmacologiche = European review for medical and pharmacological sciences = Revue europeenne pour les sciences médicales et pharmacologiques*. Jan-Feb 1995;17(1):41-50.
- 132.**Drexler AR, Mur EJ, Gunther VC. Efficacy of an EMG-biofeedback therapy in fibromyalgia patients. A comparative study of patients with and without abnormality in (MMPI) psychological scales. *Clinical and experimental rheumatology*. Sep-Oct 2002;20(5):677-682.
- 133.**Buckelew SP, Conway R, Parker J, et al. Biofeedback/relaxation training and exercise interventions for fibromyalgia: a prospective trial. *Arthritis care and research : the official journal of the Arthritis Health Professions Association*. Jun 1998;11(3):196-209.
- 134.**Cameron LD, Nicholls G. Expression of stressful experiences through writing: effects of a self-regulation manipulation for pessimists and optimists. *Health psychology : official journal of the Division of Health Psychology, American Psychological Association*. Jan 1998;17(1):84-92.
- 135.**Greenberg MA, Wortman CB, Stone AA. Emotional expression and physical health: revising traumatic memories or fostering self-regulation? *Journal of personality and social psychology*. Sep 1996;71(3):588-602.
- 136.**Petrie KJ, Booth RJ, Pennebaker JW, Davison KP, Thomas MG. Disclosure of trauma and immune response to a hepatitis B vaccination program. *Journal of consulting and clinical psychology*. Oct 1995;63(5):787-792.
- 137.**Esterling BA, Antoni MH, Fletcher MA, Margulies S, Schneiderman N. Emotional disclosure through writing or speaking modulates latent Epstein-Barr virus antibody titers. *Journal of consulting and clinical psychology*. Feb 1994;62(1):130-140.
- 138.**Van Houdenhove B, Neerinx E, Lysens R, et al. Victimization in chronic fatigue syndrome and fibromyalgia in tertiary care: a controlled study on prevalence and characteristics. *Psychosomatics*. Jan-Feb 2001;42(1):21-28.
- 139.**Broderick JE, Junghaenel DU, Schwartz JE. Written emotional expression produces health benefits in fibromyalgia patients. *Psychosomatic medicine*. Mar-Apr 2005;67(2):326-334.

- 140.**Thieme K, Flor H, Turk DC. Psychological pain treatment in fibromyalgia syndrome: efficacy of operant behavioural and cognitive behavioural treatments. *Arthritis research & therapy*. 2006;8(4):R121.
- 141.**Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. *JAMA : the journal of the American Medical Association*. Nov 17 2004;292(19):2388-2395.
- 142.**Wolfe F, Zhao S, Lane N. Preference for nonsteroidal antiinflammatory drugs over acetaminophen by rheumatic disease patients: a survey of 1,799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. *Arthritis and rheumatism*. Feb 2000;43(2):378-385.
- 143.**Goldenberg DL, Felson DT, Dinerman H. A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. *Arthritis and rheumatism*. Nov 1986;29(11):1371-1377.
- 144.**Society AP. Guideline for the Management of Pain in Fibromyalgia, American Pain Society Clinical Practice Guidelines. <http://www.ampainsoc.org>. 2011.
- 145.**Clauw DJ. Fibromyalgia: update on mechanisms and management. *Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases*. Apr 2007;13(2):102-109.
- 146.**Chu LF, Angst MS, Clark D. Opioid-induced hyperalgesia in humans: molecular mechanisms and clinical considerations. *The Clinical journal of pain*. Jul-Aug 2008;24(6):479-496.
- 147.**Goldenberg DL. Pharmacological treatment of fibromyalgia and other chronic musculoskeletal pain. *Best practice & research. Clinical rheumatology*. Jun 2007;21(3):499-511.
- 148.**Biasi G, Manca S, Manganelli S, Marcolongo R. Tramadol in the fibromyalgia syndrome: a controlled clinical trial versus placebo. *International journal of clinical pharmacology research*. 1998;18(1):13-19.
- 149.**Bennett RM, Kamin M, Karim R, Rosenthal N. Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. *The American journal of medicine*. May 2003;114(7):537-545.
- 150.**Holman AJ. Pragmatic consideration of recent randomized, placebo-controlled clinical trials for treatment of fibromyalgia. *Current pain and headache reports*. Dec 2008;12(6):393-398.
- 151.**Perahia DG, Pritchett YL, Desai D, Raskin J. Efficacy of duloxetine in painful symptoms: an analgesic or antidepressant effect? *International clinical psychopharmacology*. Nov 2006;21(6):311-317.
- 152.**Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. *Medical care*. Jun 1992;30(6):473-483.
- 153.**Arnold LM, Keck PE, Jr., Welge JA. Antidepressant treatment of fibromyalgia. A meta-analysis and review. *Psychosomatics*. Mar-Apr 2000;41(2):104-113.
- 154.**Crofford LJ, Mease PJ, Simpson SL, et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin. *Pain*. Jun 2008;136(3):419-431.
- 155.**Staud R. Sodium oxybate for the treatment of fibromyalgia. *Expert opinion on pharmacotherapy*. Aug 2011;12(11):1789-1798.
- 156.**Hoeldtke RD, Davis KM. The orthostatic tachycardia syndrome: evaluation of autonomic function and treatment with octreotide and ergot alkaloids. *The Journal of clinical endocrinology and metabolism*. Jul 1991;73(1):132-139.
- 157.**Sommer C, Hauser W, Berliner M, et al. [Pharmacological treatment of fibromyalgia syndrome]. *Schmerz*. Jun 2008;22(3):313-323.
- 158.**Feldmann C. A fibro-friendly workplace. *Fibromyalgia Aware*. 2009;19:24-25.
- 159.**Barrett D. When FM leads to a career change. *Fibromyalgia Aware*. 2009;19:22-23.
- 160.**Daraz L, Macdermid JC, Wilkins S, Gibson J, Shaw L. The quality of websites addressing fibromyalgia: an assessment of quality and readability using standardised tools. *BMJ open*. Jan 1 2011;1(1):e000152.
- 161.**Lorig KR, Ritter PL, Laurent DD, Plant K. The internet-based arthritis self-management program: a one-year randomized trial for patients with arthritis or fibromyalgia. *Arthritis and rheumatism*. Jul 15 2008;59(7):1009-1017.
- 162.**Williams DA, Kuper D, Segar M, Mohan N, Sheth M, Clauw DJ. Internet-enhanced management of fibromyalgia: a randomized controlled trial. *Pain*. Dec 2010;151(3):694-702.
- 163.**Menga G, Dupre BJ, Ganthier C et al.,. Fibromyalgia: Can online cognitive behavioral therapy help? (Abstract). *Arthritis and rheumatism*. 2011;63 supp(10):937.
- 164.**Collinge W SR, Yarnold PR.,. An internet-based intervention for fibromyalgia self-management: initial design and alpha test. *Optimal Data Analysis*. 2010;1(1):163-175. Available online at : <http://optimaldataanalysis.com/journal.htm>.
- 165.**Wierwille L. Fibromyalgia: diagnosing and managing a complex syndrome. *Journal of the American Academy of Nurse Practitioners*. Apr 2012;24(4):184-192.
- 166.**Jahan F, Nanji K, Qidwai W, Qasim R. Fibromyalgia syndrome: an overview of pathophysiology, diagnosis and management. *Oman medical journal*. May 2012;27(3):192-195.
- 167.**Cazzola M, Sarzi Puttini P, Stisi S, et al. Fibromyalgia syndrome: definition and diagnostic aspects. *Reumatismo*. Jul-Sep 2008;60 Suppl 1:3-14.
- 168.**Bellato E, Marini E, Castoldi F, et al. Fibromyalgia syndrome: etiology, pathogenesis, diagnosis, and treatment. *Pain research and treatment*. 2012;2012:426130.



It's all in the formula

Disclaimer

The material in this ebook is provided for information and educational purposes only. It is not intended to be a substitute for a health care provider's consultation. Please consult your health care provider about the applicability of any opinions or recommendations with respect to your own symptoms or medical conditions.

The Publisher, author and website shall have neither liability nor responsibility to any person or entity with respect to any loss, damage, sickness or injury caused or alleged to be caused directly or indirectly by information contained in this eBook.

Copyright

This eBook, FIBROMYALGIA SYNDROME, WHAT DO WE KNOW ABOUT CAUSES AND TREATMENT OPTIONS?, has been confirmed as the work of Natural Prescriptions CC. As such no unauthorised use, copying or publication of all or any part of this ebook will be allowed in any form including electronic, audio or print media without written permission from Natural Prescriptions CC.